definiens: the confidentiality agreement executed between [ * * * ] ; means the specific Antigen ( or part thereof ) coded for by reference to the sequence set out inSchedule 12 ; means all data, information, know - how and other intellectual property andresults arising from the ALLCAR19 Study or the CARPALL Study including the protocol for the ALLCAR19Study and for the CARPALL Study and the Test and Regulatory Data resulting from the ALLCAR19 Study andfrom the CARPALL Study ; means UCL Hospitals NHS Foundation Trust, The ChristieNHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Great Ormond Street Hospital forChildren NHS Foundation Trust, Manchester University NHS Foundation Trust and such other NHS Trusts asmay act as study sites in respect of the ALLCAR19 Study and/or the CARPALL Study from time to time ; means ( i ) the [ * * * ] Contract, ( ii ) the [ * * * ] Grant, ( iii ) the [ * * * ] Agreementsand ( iv ) the agreements entered into between UCL and [ * * * ] in respect of their conduct of the CARPALL Studyor the ALLCAR19 Study, as applicable ; means all uses without restriction except for Exploitation of the TetCAR CD19 Field Product, including any activities of research, development or commercialisation of such TetCAR CD19 Field Product ; means any CAR product(s ) or therapy(ies ) which, as its sole mechanism of targetingand engaging with a tumour cell, solely binds to the CD19 Antigen and does not bind to any other Antigen(s ) forthe purpose of determining the selectivity for the tumour cell ; means the specific [ * * * ] defined in Schedule 1 under the [ * * * ] Program ; has the meaning set out in Clause 2.4 ; has the meaning set out in Clause 2.5 ; has the meaning set out in Clause 2.4 ; means [COMPANY] ’s rights under Clauses 2.4 and 2.5 ; means any product or therapy which ( i ) targets [ * * * ] and is covered by, uses, incorporates orhas been developed using any of the [ * * * ] Program IP ; or ( ii ) targets [ * * * ] and has been developed using any ofthe UCL Background IP or Manufacturing Know - How ; or ( iii ) were it not for the license to [ * * * ] Program IPhereunder, would otherwise infringe any Patent Right licensed hereunder under the [ * * * ] Program IP ; CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT . THE COPY FILEDHEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST . OMISSIONS AREDESIGNATED [ * * * ] . A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THESECURITIES AND EXCHANGE COMMISSION